Publications
Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors." Journal of the American Chemical Society 134, no. 40 (2012): 16480-16483.
"Photoregulated gene expression in human cells with light-inducible engineered transcription factors." Asme 2012 Summer Bioengineering Conference, Sbc 2012 (2012): 351-352.
"Engineered Proteins for Controlling Gene Expression." 1 (2013): 125-138.
"Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111)." Molecular Therapy 21, no. 11 (2013): 2130.
"Gene Delivery into Cells and Tissues." (2013): 687-723.
"Highly active zinc-finger nucleases by extended modular assembly." Genome Research 23, no. 3 (2013): 530-538.
"How vinculin regulates force transmission." Proceedings of the National Academy of Sciences of the United States of America 110, no. 24 (2013): 9788-9793.
"Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients." Molecular Therapy 21, no. 9 (2013): 1718-1726.
"RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nature Methods 10, no. 10 (2013): 973-976.
"The role of single-cell analyses in understanding cell lineage commitment." Biotechnology Journal 8, no. 4 (2013): 397-407.
"Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In Molecular Therapy, S93. Vol. 21. 2013.
"Synergistic and tunable human gene activation by combinations of synthetic transcription factors." Nat Methods 10, no. 3 (2013): 239-242.
"Targeted plasmid integration into the Human Genome by engineered recombinases." Topics in Current Genetics 23 (2013): 267-284.
"Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases." Molecular Therapy 21, no. 2 (2013): 266-268.
"Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering." In Osteoarthritis and Cartilage, S282-S283. Vol. 21. 2013.
"ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering." Trends in Biotechnology 31, no. 7 (2013): 397-405.
"Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 835-839.
"Comparing genome editing technologies." Genetic Engineering & Biotechnology News 34, no. 5 (2014): 1, 32-34.
"CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (2014): 476-477.
"A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (2014): 940-947.
"Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (2014): 188-197.
"Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods (San Diego, Calif.) 69, no. 2 (2014): 188-197.
"Genome engineering: the next genomic revolution." Nature Methods 11, no. 10 (2014): 1009-1011.
"Light-inducible gene regulation with engineered zinc finger proteins." Methods in Molecular Biology (Clifton, N.J.) 1148 (2014): 89-107.
"Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector." Nucleic Acids Research 42, no. 19 (2014).
"